Recent News

AACR II: Early Results With Dual Inhibitors of IGF and CDK4/6 in Lung Cancer

AACR II: Adding Interferon-Gamma to Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer

Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma

Immune-Mediated Adverse Events With Concomitant Radiotherapy and Immunotherapy

Interim Results of Trastuzumab Deruxtecan in HER2-Mutated Metastatic NSCLC

Combining IL-7 With Pembrolizumab in Metastatic Triple-Negative Breast Cancer

EHA25 Virtual: Adding Isatuximab to Front-Line Standard of Care in High-Risk Myeloma

AACR II: Flat Dosing of Nivolumab in Patients Previously Treated for NSCLC

Subcutaneous Combination Therapy Approved by FDA for HER2-Positive Breast Cancer

HER2-Targeted Therapy With Trastuzumab Deruxtecan in Lung Cancer

Pembrolizumab Approved by FDA for Cutaneous Squamous Cell Carcinoma

ASCO20: 3-Year Update on Nivolumab Plus Ipilimumab as First-Line Treatment of NSCLC

ASCO20: Tucatinib Combination Therapy for Breast Cancer With Brain Metastases

EHA25 Virtual: Single-Agent Belantamab Mafodotin in Resistant Myeloma

ASCO20: Venetoclax Plus Obinutuzumab in Treatment-Naive CLL

ASCO20: Update on BCMA-Directed CAR-T Cell Therapy for Resistant Myeloma

ASCO20: Tiragolumab Plus Atezolizumab for PD-L1–Selected NSCLC

First-in-Class Immunotherapy With Azacitidine Under Study in AML

ASCO20: Can Radioiodine Plus Durvalumab Improve Outcomes in Resistant Thyroid Cancer?

ASCO20: KEYNOTE-355 Trial of Pembrolizumab Plus Chemotherapy in Triple-Negative Breast Cancer

ASCO20: Antibody-Drug Conjugate Active in CEACAM5-Expressing Nonsquamous NSCLC

ASCO20: Final Results From GENUINE Trial of Ublituximab Plus Ibrutinib in CLL

EHA25 Virtual: Adding Isatuximab to Carfilzomib and Dexamethasone in Resistant Myeloma

Biologic Therapies for Patient With Both Lung Cancer and Multiple Myeloma

ASCO20: Does Adding Trastuzumab to Radiotherapy Decrease Recurrence of Breast Cancer?

ASCO20: Update on Orvacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma

ASCO20: Longer-Term Follow-Up Supports Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma

ASCO20: Autologous Tumor Immunotherapy Plus Atezolizumab in Recurrent Ovarian Cancer

ASCO20: Trastuzumab Deruxtecan in HER2-Expressing Metastatic Colorectal Cancer

ASCO20: Cabozantinib Plus Atezolizumab for Castration-Resistant Prostate Cancer

EHA25 Virtual: Phase III Trial to Study Acalabrutinib-Based Combination in CLL

ASCO20: Antibody-Drug Conjugate Plus Bevacizumab in Platinum-Agnostic Ovarian Cancer

ASCO20: Treating Anaplastic Thyroid Cancer Based on Driver Mutations

ASCO20: Adding Elotuzumab to Bortezomib-Based Therapies for High-Risk Multiple Myeloma

ASCO20: Combination Immunotherapy for Aggressive Thyroid Cancers

ASCO20: Selinexor-Based Combination Therapy for Resistant Multiple Myeloma

Can Viral Immunotherapy Reverse Platinum Resistance in Ovarian Cancer?

ASCO20: Adding T-DM1 to Targeted Therapy for High-Risk Early Breast Cancer

ASCO20: ‘Modest Antitumor Activity’ for Pembrolizumab in Recurrent Ovarian Cancer

ASCO20: Lenvatinib Plus Pembrolizumab in Radioiodine-Refractory Thyroid Cancer

Chemotherapy-Free Treatment of CLL: Acalabrutinib With or Without Obinutuzumab

ASCO20 Preview: Should Pembrolizumab Replace Chemotherapy in First-Line Treatment of Some Colorectal Cancers?

Novel Antibody-Drug Conjugate Under Study in Resistant Multiple Myeloma

FDA Approves Chemotherapy Plus Immunotherapy Combination in First-Line Treatment of Resistant NSCLC

Use of Live Attenuated Vaccines in Teenagers Treated With Imatinib for CML

Combination Therapy of Paclitaxel, Carboplatin, and Pembrolizumab in Ovarian Cancer

Biologic Therapies for Patient With Both Multiple Myeloma and Lung Cancer

FDA Approves Atezolizumab for Metastatic NSCLC With High PD-L1 Expression

Ofatumumab Treatment and Rare Viral Infection of the Brain : A Case Study in CLL

COVID-19 and Multiple Myeloma: 60-Year-Old Man Successfully Treated With Tocilizumab

Immunotherapy for Low–Mutational Burden Prostate Cancer

AACR 2020: Final IMpower150 Analysis of Chemoimmunotherapy in Nonsquamous Lung Cancer

AACR 2020: Dendritic Cell Vaccines for Advanced Ovarian Cancers